This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Infliximab: mechanism of action

The active substance in infliximab is a monoclonal antibody.1,2 A monoclonal antibody is an antibody (a type of protein) which recognises and binds to a specific structure (called an antigen) in the body1,2

The antigen that infliximab recognises is the cytokine (a messenger protein) tumour necrosis factor alpha (TNF-ɑ)1,2

Infliximab is a chimeric antibody, where the antigen-binding portion is of murine origin, whereas the constant region is of human origin3,4

TNF-alpha is involved in driving inflammation and is found at high levels in patients with the immune-mediated inflammatory diseases that infliximab is used to treat. By blocking TNF-ɑ, infliximab improves inflammation and other symptoms of those diseases1,2

Watch our video to learn how infliximab inhibits the functional activity of TNF-ɑ

Please refer to the SmPC before prescribing INFLECTRA®. Please click here to be directed to the SmPC.

References:European Public Assessment Report – Summary for the public: Remicade™. November 2018. Available at: https://www.ema.europa.eu/en/documents/overview/remicade-epar-summary-public_en.pdf. Accessed May 2023.European Public Assessment Report – Summary for the public: INFLECTRA®. September 2013. Available at: https://www.ema.europa.eu/en/documents/overview/inflectra-epar-summary-public_en.pdf. Accessed May 2023.European Public Assessment Report: Remicade™. 19 January 2012. Available at: https://www.ema.europa.eu/en/documents/variation-report/remicade-h-c-240-ii-0150-epar-assessment-report-variation_en.pdf. Accessed May 2023.European Public Assessment Report: INFLECTRA®. 27 June 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/human/002778/ WC500151490.pdf. Accessed May 2023.
Infliximab
INFLECTRA® dosing

Read about dosing and administration of INFLECTRA®

Find out more Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0145 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0176. January 2023